Bladder Cancer: Symptoms, Causes & Treatment

Bladder cancer is the most common urinary tract malignancy and the tenth most prevalent cancer globally, affecting men four times more frequently than women. Urothelial carcinoma (transitional cell carcinoma) accounts for more than 90% of cases in high-income countries, arising from the urothelial lining that extends from the renal pelvis to the urethra. Bladder cancer has the highest recurrence rate of any solid tumor: over 70% of non-muscle-invasive cases recur after treatment, necessitating lifelong surveillance.

Tumors are classified by depth of invasion: non-muscle-invasive bladder cancer (NMIBC, Stages Ta/T1/CIS) is confined to the mucosa and lamina propria; muscle-invasive bladder cancer (MIBC, T2 and beyond) penetrates the detrusor muscle and carries substantially worse prognosis. Carcinoma in situ (CIS) is a flat, high-grade lesion with significant potential for progression even when non-invasive. NMIBC is managed endoscopically (TURBT) with intravesical BCG immunotherapy or chemotherapy; MIBC requires radical cystectomy or definitive chemoradiation.

Painless hematuria is the cardinal presenting symptom in 85% of patients and should always trigger urgent urological evaluation to exclude malignancy. Major risk factors include cigarette smoking (3× risk), occupational exposure to aromatic amines (dye, rubber, leather industries), chronic bladder irritation (schistosomiasis), prior pelvic radiation, and cyclophosphamide therapy.

• Painless gross or microscopic hematuria — present in 85% of cases; always requires investigation
• Irritative voiding symptoms: frequency, urgency, dysuria (especially in CIS)
• Pelvic or flank pain in locally advanced disease
• Constitutional symptoms (weight loss, fatigue, anorexia) in metastatic disease

• Cigarette smoking — the single largest risk factor, responsible for ~50% of cases; 3× relative risk
• Occupational chemical exposure: aromatic amines in dye, rubber, leather, aluminum, and printing industries
• Schistosoma haematobium infection: linked to squamous cell carcinoma in endemic regions (Africa, Middle East)
• Prior pelvic radiotherapy or cyclophosphamide chemotherapy
• Chronic bladder irritation from indwelling catheters, calculi, or recurrent infections

Initial evaluation: urinalysis and urine cytology; CT urogram to evaluate the upper urinary tract and detect tumor extent. Cystoscopy with transurethral resection of bladder tumor (TURBT) is the gold standard for diagnosis and initial treatment of NMIBC, providing both tissue and staging information. Muscle must be included in resection specimens. MRI pelvis for local staging of MIBC; CT chest for metastatic assessment. Urine biomarkers (NMP22, BTA, UroVysion FISH) supplement surveillance.

NMIBC: TURBT followed by risk-stratified intravesical therapy — BCG immunotherapy for high-risk (CIS, high-grade T1) reduces recurrence and progression; mitomycin C for low-risk. Maintenance BCG 1–3 years. Surveillance cystoscopy every 3–6 months indefinitely. MIBC: radical cystectomy with neoadjuvant cisplatin-based chemotherapy (GC or dose-dense MVAC) is standard; trimodality bladder-preservation (maximal TURBT + chemoradiation) is an option for selected patients. Metastatic disease: platinum-based chemotherapy + PD-L1 checkpoint inhibitors (pembrolizumab, atezolizumab); enfortumab vedotin-pembrolizumab as first-line in ineligible patients.

• High recurrence rates in NMIBC demanding lifelong cystoscopic surveillance
• Disease progression to muscle-invasive or metastatic stage in inadequately treated cases
• Radical cystectomy — permanent urinary diversion with significant impact on body image and quality of life
• Metastases to lymph nodes, liver, lung, and bone in advanced disease

• Smoking cessation is the most impactful preventive measure; risk decreases progressively after quitting
• Occupational hygiene and protective equipment for workers exposed to aromatic amines
• Schistosomiasis control programs in endemic regions
• Prompt urological evaluation of any hematuria — early diagnosis dramatically improves outcomes